CGRP-targeted therapies combined with lifestyle changes cut migraine frequency nearly in half — from 26.5 to 14 days per month — in pediatric chronic migraine patients who had failed other treatments.
26.5 → 14 migraine days/monthMedian reduction in migraine frequency among pediatric patients receiving CGRP-targeted therapy over 12 months
What the researchers found
In 10 pediatric chronic migraine patients who had failed at least 2 prior preventive therapies, CGRP monoclonal antibodies or antagonists combined with structured lifestyle modifications produced significant improvements over 12 months:
- Migraine frequency decreased from a median of 26.5 to 14 days per month (statistically significant)
- Acute analgesic use dropped from 14 to 5 days per month (statistically significant)
- Disability scores improved significantly (p=0.037)
All patients had severe baseline burden (PedMIDAS score ≥30, ≥8 migraine days per month), making these reductions clinically meaningful for this difficult-to-treat population.
Why it matters
CGRP-targeted therapies have transformed adult migraine care, but their use in children remains largely uncharted territory. Pediatric chronic migraine is especially debilitating — it affects school attendance, social development, and quality of life. This study provides early evidence that these peptide-targeting treatments are safe and effective in young patients, potentially opening a new treatment avenue for children who haven't responded to standard medications.
How the study worked
This was a retrospective study of 10 pediatric chronic migraine patients treated at Gangnam Severance Hospital in Korea from 2021 to 2024. Inclusion criteria required a PedMIDAS disability score of 30 or higher, failure of more than 2 preventive therapies, and at least 8 migraine days per month. Patients received CGRP monoclonal antibodies or antagonists alongside structured sleep, dietary, and exercise interventions. Outcomes including migraine frequency, neuropsychological measures, and lifestyle adherence were tracked over 12 months.
What this study cannot tell us
The sample size of only 10 patients is very small, limiting statistical power and generalizability. The retrospective design means there was no control group — improvements could partly reflect the lifestyle modifications, natural disease fluctuation, or placebo effects. The study was conducted at a single Korean hospital, and results may not generalize to other populations. The abstract also appears to have incomplete p-values, suggesting possible formatting issues in the original publication.
How to read the evidence
This is a small retrospective study with only 10 patients and no control group. While the results are encouraging and the 12-month follow-up is valuable, the very small sample size and lack of randomization significantly limit the strength of evidence. This should be considered preliminary data supporting further investigation.
When this study was published
Published in 2025 with data from 2021-2024, this is among the most recent studies on CGRP-targeted therapies in pediatric migraine and reflects current clinical practice.
The bigger picture
CGRP-targeted therapies are well-established for adult migraine, but regulatory approval and evidence for pediatric use lag far behind. This study contributes to a small but growing body of evidence supporting their use in children. As more pediatric data accumulates, it may inform updated treatment guidelines and potentially lead to formal approval of these peptide-targeted drugs for younger patients.
Questions still open
- Would a larger, controlled trial confirm that CGRP-targeted therapies are effective and safe in pediatric migraine patients across different populations?
- How much of the improvement was attributable to the CGRP therapy versus the structured lifestyle interventions?
- Are there long-term safety concerns with CGRP-targeted therapies in developing children and adolescents?
Common questions
Are CGRP-targeted therapies approved for use in children?
Why were lifestyle changes included alongside the medication?
Read the original research
Effectiveness and Safety of CGRP-Targeted Therapies Combined with Lifestyle Modifications for Chronic Migraine in Korean Pediatric Patients: A Retrospective Study.
Brain sciences, 15(5)
Citation
Na, Ji-Hoon; Jeon, Hayoon; Shim, Ji-Eun; Lee, Hyunjoo; Lee, Young-Mock. (2025). Effectiveness and Safety of CGRP-Targeted Therapies Combined with Lifestyle Modifications for Chronic Migraine in Korean Pediatric Patients: A Retrospective Study.. Brain sciences, 15(5). https://doi.org/10.3390/brainsci15050493